



ORAL PRESENTATION

Open Access

A rare polymorphism in *Toll Like Receptor 2* is associated with systemic sclerosis phenotype and increases production of inflammatory mediators

Jasper CA Broen^{1*}, Lara Bossini-Castillo², Lenny van Bon¹, Madelon C Vonk¹, Hanneke Knaapen¹, Lorenzo Beretta³, Blanca Rueda², Roger Hesselstrand⁴, Ariane Herrick⁵, Jane Worthington⁵, Nicholas Hunzelmann⁶, Christopher Denton⁷, Carmen Fonseca⁷, Gabriela Riemekasten⁸, Hans Kiener⁹, Raffaella Scorza³, Carmen P Simeon¹⁰, Norberto Ortego-Centeno¹¹, Miguel A Gonzalez-Gay¹², Paolo Airo¹³, Marieke JH Coenen¹⁴, Javier Martin², Timothy RDJ Radstake¹

From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011

Background

Toll like receptors play an important role in fine-tuning innate immune responses, but genetic variations in *TLR* genes have been shown previously to augment immune responses and susceptibility to autoimmune disease.

Aim

To investigate whether polymorphisms in *toll like receptor* (*TLR*) genes, previously reported to be associated with immune mediated diseases are implicated in systemic sclerosis (SSc).

Methods

We genotyped 14 polymorphisms in the *TLR 2, 4, 7, 8* and *9* genes in a discovery cohort comprising 452 SSc patients and 537 controls and a replication cohort consisting of 1170 SSc patients and 925 controls. Furthermore we analyzed 15 year follow-up data from 964 patients to assess the potential association of *TLR* variants with the development of disease complications. Next to this, we analyzed the functional impact of the associated polymorphism on monocyte derived and myeloid dendritic cells.

Results

Exploiting the discovery cohort, we observed that a rare functional polymorphism in *TLR2* (Pro631His), was associated with anti-topoisomerase positivity ($p=0.003$ OR

2.24 95%CI:1.24-4.04). This observation was validated in the replication cohort ($p=0.0001$ OR 2.73 95%CI:1.85-4.04). In addition, the replication cohort also revealed an association between the *TLR2* variant with the diffuse subform of the disease and the development of pulmonary arterial hypertension, respectively ($p=0.02$, Log-Rank $p=0.003$, Cox proportional hazards ratio: 5.61 ((95%CI 1.53-20.58)). Functional analysis revealed that monocyte derived dendritic cells carrying the Pro63His variant produce more inflammatory mediators (TNFalpha and IL-6) upon *TLR2* mediated stimulation (both $p<0.0001$).

Conclusion

The rare *TLR2*Pro631His variant is robustly associated with anti-topoisomerase positivity, diffuse SSc and the development of PAH. Besides, this variant influences *TLR2* mediated cell responses. Further research is necessary to reveal the precise role of *TLR2* in the disease pathogenesis of SSc.

Author details

¹Dept. of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. ²Instituto de Parasitología y Biomedicina, CSIC, Granada, Spain. ³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Italy. ⁴Dept. of Rheumatology, Lund University, Lund, Sweden. ⁵Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, UK. ⁶Dept. of Dermatology, University of Cologne, Germany. ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, UK. ⁸Dept. of Rheumatology and Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz institute, Berlin, Germany. ⁹Dept. of Internal Medicine, Division of Rheumatology, University of Vienna, Austria. ¹⁰Servicio de

¹Dept. of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Full list of author information is available at the end of the article

Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain. ¹¹For the Spanish Systemic Sclerosis group; Servicio de Medicina Interna, Hospital Universitario Central de Asturias, Oviedo, Spain. ¹²Servicio de Medicina Interna, Hospital Clinico Universitario, Granada, Spain. ¹³Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili, Brescia, Italy. ¹⁴Dept. of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

Published: 23 November 2011

doi:10.1186/1479-5876-9-S2-O4

Cite this article as: Broen *et al.*: A rare polymorphism in *Toll Like Receptor 2* is associated with systemic sclerosis phenotype and increases production of inflammatory mediators. *Journal of Translational Medicine* 2011 9(Suppl 2):O4.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

